References
- Knoebl P, Marco P, Baudo F, et al. Demographic and clinical data in acquired hemophilia A: results from the European acquired haemophilia registry (EACH2). J Thromb Haemost. 2012;10:622–631.
- Franchini M, Vaglio S, Marano G, et al. Acquired hemophilia A: a review of recent data and new therapeutic options. Hematology. 2017;22:514–520.
- Kruse‐Jarres R, Kempton CL, Baudo F, et al. Acquired hemophilia A: updated review of evidence and treatment guidance. Am J Hematol. 2017;92:695–705.
- Baudo F, Collins P, Huth-Kühne A, et al. Management of bleeding in acquired hemophilia A: results from the European acquired haemophilia (EACH2) registry. Blood. 2012;120:39–46.
- Collins P, Baudo F, Knoebl P, et al. Immunosuppression for acquired hemophilia A: results from the European acquired haemophilia registry (EACH2). Blood. 2012;120:47–55.
- Grossin D, Broner J, Arnaud E, et al. Hémophilie acquise auto-immune: quelle est la place du rituximab dans la stratégie thérapeutique? Réflexion à partir d’une série monocentrique de 8 patients et revue de la littérature [Acquired autoimmune haemophilia: where is the place of rituximab in the treatment strategy? Reflection from a monocentric series of 8 patients and literature review]. La Revue de Médecine Interne [Internet]. 2019 Mar 21 [cited 2019 Jun 6]. Available from: http://www.sciencedirect.com/science/article/pii/S0248866319300566 French.
- Dagklis A, Fazi C, Sala C, et al. The immunoglobulin gene repertoire of low-count chronic lymphocytic leukemia (CLL)–like monoclonal B lymphocytosis is different from CLL: diagnostic implications for clinical monitoring. Blood. 2009;114:26–32.